Doç. Dr. NEYRAN KERTMEN

Yayın Ağı

Makaleler 40

1. Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literature

KERTMEN N., KAVGACI G., Koc I., PARLAK SAĞOL Ş., IŞIKAY A. İ., YAZICI G.

ONCOLOGY LETTERS , sa.3, 2025 (SCI-Expanded, Scopus)

2. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases

KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.

CANCER CONTROL , 2025 (SCI-Expanded, Scopus)

3. Hypo-fractionated Stereotactic Re-Irradiation Outcomes For Recurrent Glioblastoma

Yilmaz M. T., KAHVECİOĞLU A., Mohammadipur S., Zorlu F., Oge K., KERTMEN N., et al.

RADIOTHERAPY AND ONCOLOGY , 2024 (SCI-Expanded, Scopus)

4. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Yilmaz M. T., KAHVECİOĞLU A., YAZICI G., Mohammadipour S., KERTMEN N., Cifci G. C., et al.

Journal of Neuro-Oncology , cilt.167, sa.2, ss.295-303, 2024 (SCI-Expanded, Scopus)

5. Acute heart failure following pazopanib treatment: a literature review featuring two case reports

KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.

Anti-Cancer Drugs , cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)

6. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.

Current Oncology , cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)

7. Low-grade glial tumors: The experience of an oncology hospital in Türkiye

CEYLAN S., KERTMEN N., YAZICI G., KARS A.

Acta Medica , cilt.54, sa.2, ss.151-156, 2023 (TRDizin)

8. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)

9. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer

KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.

Biomarkers in Medicine , cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)

10. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

11. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer

YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.9, 2022 (SCI-Expanded, Scopus)

13. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

15. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.

FUTURE ONCOLOGY , cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

17. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

18. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?

Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.

CUREUS , cilt.13, sa.6, 2021 (ESCI)

21. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma

BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.5, ss.1230-1233, 2020 (SCI-Expanded, Scopus)

23. Depression and anxiety in oncology nurses.

Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

24. Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers

Karakas Y., KERTMEN N., LAÇİN Ş., Aslan A., DEMİR M., ATEŞ Ö., et al.

JOURNAL OF BUON , cilt.22, sa.3, ss.623-627, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience

Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.

JOURNAL OF BUON , cilt.21, sa.4, ss.826-831, 2016 (SCI-Expanded, Scopus)

26. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors

ATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., et al.

SPRINGERPLUS , cilt.5, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.

JOURNAL OF BUON , cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

28. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75

Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.2, ss.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)

29. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.

TUMORI J , cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality

Solak M., Turkoz F. P., Keskin O., AKSOY S., BABACAN T., Sarici F., et al.

JOURNAL OF BUON , cilt.20, sa.3, ss.737-745, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

31. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis

BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.

JOURNAL OF BUON , cilt.20, sa.2, ss.479-486, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer

Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.22-27, 2015 (SCI-Expanded, Scopus)

33. Comparison of three different induction regimens for nasopharyngeal cancer

KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.

Asian Pacific Journal of Cancer Prevention , cilt.16, sa.1, ss.59-63, 2015 (SCI-Expanded, Scopus)

34. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab

ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.

JOURNAL OF BUON , cilt.20, sa.1, ss.349, 2015 (SCI-Expanded, Scopus)

35. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature

Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.348, 2015 (SCI-Expanded, Scopus)

36. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats

KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.

Anticancer Research , 2015 (SCI-Expanded, Scopus)

37. which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats

KERTMEN N.

Hacettepe Journal of Biology and Chemistry , cilt.15, ss.1056-1058, 2015 (Scopus, TRDizin)

38. Molecular subtypes in patients with inflammatory breast cancer; A single center experience

KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients

BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., et al.

JOURNAL OF BUON , cilt.20, sa.1, ss.50-56, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Association between common risk factors and molecular subtypes in breast cancer patients

Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.

BREAST , cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 19

1. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

2. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Depression and anxiety in oncology nurses.

KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU İNANÇ G., et al.

2018 ASCO Annual Meeting, Amerika Birleşik Devletleri, 5 - 08 Haziran 2018, ss.18552, (Tam Metin Bildiri)

4. Onkoloji Hemşirelerinde depresyon ve anksiyete

KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU G. İ., et al.

22.ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)

5. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ

KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.

22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)

6. Intravenous ferric carboxymaltose treatment in cancer patients

ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

7. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma

ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.

2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)

8. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever

ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.

2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)

9. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer

Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.

ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

10. Neuroendocrine breast cancer A single center experience

TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.

2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

11. Tumor locations significantly affect disease free survival and overall survival

BUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.

2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)

12. Signet ring cell carcinoma of breast: Single center experience.

AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

13. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.

Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.

19. The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.

Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

249

H-İndeks (WoS)

Atıf (Scopus)

115

H-İndeks (Scopus)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler